ahlam1399
08-23-2016, 01:28 AM
BRIEF-Sophiris Bio currently evaluating options to further advance clinical development of Topsalysin
* Currently evaluating options to further advance clinical
development of topsalysin – sec filinghttp://feeds.feedburner.com/~ff/reuters/bondsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/bondsNews?a=cbt52t0QzC0:wFmd6DjlvXM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/bondsNews?i=cbt52t0QzC0:wFmd6DjlvXM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/bondsNews?a=cbt52t0QzC0:wFmd6DjlvXM:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/bondsNews?i=cbt52t0QzC0:wFmd6DjlvXM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/bondsNews?a=cbt52t0QzC0:wFmd6DjlvXM:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/bondsNews/~4/cbt52t0QzC0
* Currently evaluating options to further advance clinical
development of topsalysin – sec filinghttp://feeds.feedburner.com/~ff/reuters/bondsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/bondsNews?a=cbt52t0QzC0:wFmd6DjlvXM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/bondsNews?i=cbt52t0QzC0:wFmd6DjlvXM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/bondsNews?a=cbt52t0QzC0:wFmd6DjlvXM:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/bondsNews?i=cbt52t0QzC0:wFmd6DjlvXM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/bondsNews?a=cbt52t0QzC0:wFmd6DjlvXM:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/bondsNews/~4/cbt52t0QzC0